LEADERSHIP TEAM
Our Dedicated Team has the Drive, Skill Set and
Experience to Develop Unique Products to Serve
Dermatology Professionals and Consumers

Yael Schwartz, Ph.D.
Past Affiliations:
- RestorGenex: Board of Directors & Executive VP of PC Development
- Canterbury Laboratories, LLC
- Hygeia Therapeutics
- Sepracor (Now Sunovion): Director, Pharmacology & Discovery Research

Craig Abolin, Ph.D.
Past Affiliations:
- RestorGenex: VP, Pharmaceutical Sciences
- Canterbury Laboratories, LLC
- Hygeia Therapeutics
- Sepracor (Now Sunovion): Director, DM/PK
- Astra (Now AstraZeneca)
- Novartis

Cristina Griffin, MBA
Cristina has more than 20 years of experience as a global strategist and corporate development executive. Her career has extended across Europe, North America, and Latin America where she has directed over twenty mergers and acquisitions projects with a focus in pharmaceuticals, biotech, aesthetic dermatology and consumer healthcare. Cristina’s vast experience includes corporate strategy, equity financing, high margin product innovation, global branding and strategic alliance building.
Cristina joined Or-Genix from Cantabria Labs, Madrid, Spain where, for the past 15 years, she was the Managing Director of Corporate Development. Over the course of her career she has been a valued participant and advisor to global and Fortune 500 firms, corporate boards, and venture capital. Earlier in her career, Cristina consulted for Pfizer, Microsoft, Telfonica, Repsol, Unilever, Santander, BUPA, Ericsson and Enresa.
Cristina received her BA from the University of Wisconsin, her MA from St. John’s College, Maryland and her MBA in Global Strategic Management from Macquarie Graduate School Management, NSW, Australia. She received advanced training at the Wharton School of Business and Harvard Business School. Besides her native tongue, English, she is fluent in Spanish and Portuguese.
Board of Directors

Ethan Rigel
Or-Genix Therapeutics, Inc.Ethan is the CEO and a Founding Partner of Gore Range Capital. He has more than ten years of investing experience, spending most of his time actively working with small businesses with limited resources. During the course of his career he has invested more than $900M in companies with a combined enterprise value of greater than $2B across dozens of investments. Most of his investments have been very hands-on, with Ethan taking an extensive role in the operations of the business and helping to drive the company’s success.

Humberto C. Antunes
Or-Genix Therapeutics, Inc.Humberto has spent his career as an entrepreneur in healthcare and wellness focused on finding ways to improve the lives of people all over the world. His previous experience includes work in dermatology, ophthalmology, medical aesthetics, immunology, inflammation, cosmetics, medical devices, pharma and nutraceuticals. He is actively involved in research to address the issues arising from aging demographics, providing holistic health solutions, helping technologies converge and the digital revolution. Prior to joining Gore Range Capital, Humberto managed Galderma, a pharmaceutical company, for almost 20 years. From 2014 through 2016, he created and led Nestlé Skin Health, which endeavors to enhance quality of life by delivering science-based solutions for skin. Humberto promoted geographic expansion of the businesses he managed, created new channels and acquired new audiences. He also led many successful acquisitions, integrations, joint-ventures, license deals and divestitures. In addition, Humberto has led research teams that achieved hundreds of New Drug Applications, patent filings and clinical trials on both sides of the Atlantic. Some of his successful digital initiatives include www.derm101.com and www.acne.com.

Mary Lake Polan, MD, PhD, MPH
Or-Genix Therapeutics, Inc.Mary Lake Polan, MD, PhD, MPH is Professor and Chair Emeritus of OB-GYN at Stanford University School of Medicine. She has served on the Wyeth Board of Directors, on the Council of the Institute of Medicine, the NIH, and American Society for Reproductive Medicine, American Medical Women’s Association, and the Secretary of HHS’s Advisory Committee on Human Research Protections.
Dr. Polan has published more than 130 articles, chapters, and books in her areas of research, and in the laboratory at Stanford she focuses on reproductive endocrinology and infertility and, most recently, on gene expression patterns in uterine fibroids (benign tumors).

Daniel M. Siegel, MD, MS
Or-Genix Therapeutics, Inc.Daniel M. Siegel, MD, MS is a Clinical Professor of Dermatology at SUNY Downstate. He is past president of AAD, a diplomate of the American Board of Dermatology and the American Board of Laser Surgery. He is the recipient of the American Skin Association Public Policy and Medical Education Award and the Academy of Dermatology Presidential Citation for 5 years. He has published more than 100 articles and book chapters in medical journals and textbooks.